ReviewImmunological reviews2019
STING pathway agonism as a cancer therapeutic.
Review in Immunological reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
191 citing papers in PubMed, 1 synthesis or guideline pooled it, 322 citations in OpenAlex.
- Prognostic significance of STING expression in solid tumor: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC.Genes & diseases · 2027Review
- Evidence-steered medicine in oncology: network-aware micro-combinations that safeguard standard of care and potentially improve benefit-risk.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Leveraging Mitochondria-Endoplasmic Reticulum Functional Interplay With an On-Demand Nanoparticle to Boost mtDNA-Based STING Immunotherapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Targeted nanoparticles with triggered lysosomal escape enable anti-angiogenic immunotherapy for peritoneal metastatic colorectal cancer.Acta pharmaceutica Sinica. B · 2026Article
- Updates on intratumoral therapies in melanoma.Cancer · 2026Review
- Photocontrolled immunotherapy: a BODIPY-caged MSA-2 for spatiotemporal activation of STING with visible light.New journal of chemistry = Nouveau journal de chimie · 2026Article
- Radiolabeled Coordination Polymer-Loaded Microneedles for Synergistic Melanoma Brachytherapy-Immunotherapy via STING Activation and Pyroptosis.Exploration (Beijing, China) · 2026Article
- Review
- Detection of nuclear STING in cultured human cells and in the normal and cancer tissues.iScience · 2026Article
- AND logic nanoparticle for precision immunotherapy of metastatic cancers.Nature nanotechnology · 2026Article
- A STING-activating biomimetic mineralized nanovaccine triggers robust anti-tumor immunity.Cancer immunology, immunotherapy : CII · 2026Article
- M1 macrophage membrane-engineered PLGA nanoparticles reprogram M2 tumor-associated macrophages to enhance anti-tumor immunity in breast cancer.Journal of materials science. Materials in medicine · 2026Article
- The cGAS-STING pathway and mitochondrial metabolism: from mechanistic insights to therapeutic potential in tumor.Journal of translational medicine · 2026Review
- Review
- Dual-receptor targeting of type I dendritic cells with DNA-scaffolded nanoparticles enhances STING-licensed antitumor immunity.Science advances · 2026Article
- Innate immunity in tumour immunoediting and immunosurveillance.The EMBO journal · 2026Review
- STING agonism in brain tumours: mechanisms, challenges, and therapeutic advances.Frontiers in oncology · 2026Review
- Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma.Nature communications · 2025Article
- Genome doubling as a dynamic driver of ovarian cancer evolution: insights from single-cell sequencing.Journal of ovarian research · 2025Review
131 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The fact that a subset of human cancers showed evidence for a spontaneous adaptive immune response as reflected by the T cell-inflamed tumor microenvironment phenotype led to the search for candidate innate immune pathways that might be driving such endogenous responses. Preclinical studies indicated a major role for the host STING pathway, a cytosolic DNA sensing pathway, as a proximal event required for optimal type I interferon production, dendritic cell activation, and priming of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.